Evidence map›Paper›PMID 41339327›Full record

ArticleNature communications2025

Enhancing kinase-inhibitor activity and selectivity prediction through contrastive learning.

Yanan Tian, Ruiqiang Lu, Xiaoqing Gong, Wei Zhao, Yuquan Li, Xiaorui Wang, Xinming Jia, Qin Li, Yuwei Yang, Henry H Y Tong and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yanan TianFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.ORCID http://orcid.org/0009-0002-6791-5005
Ruiqiang LuFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Xiaoqing GongFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Wei ZhaoFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Yuquan LiState Key Laboratory of Public Big Data, College of Computer Science and Technology, Guizhou University, Guiyang, China.ORCID http://orcid.org/0000-0003-2756-0449
Xiaorui WangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0001-6893-2013
Xinming JiaFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Qin LiFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Yuwei YangFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.ORCID http://orcid.org/0009-0001-8672-9307
Henry H Y TongFaculty of Applied Sciences, Macao Polytechnic University, Macao, China.ORCID http://orcid.org/0000-0003-2687-741X
Joel P ArraisCISUC/LASI-Centre for Informatics and Systems of the University of Coimbra, Department of Informatics Engineering, University of Coimbra, Coimbra, Portugal.
Xiaojun YaoFaculty of Applied Sciences, Macao Polytechnic University, Macao, China. xjyao@mpu.edu.mo.
Huanxiang LiuFaculty of Applied Sciences, Macao Polytechnic University, Macao, China. hxliu@mpu.edu.mo.ORCID http://orcid.org/0000-0002-9284-3667

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Developing selective kinase inhibitors is challenging due to the conserved kinase structures and costly kinome profiling experiments, highlighting the need for accurate prediction of kinase-inhibitor affinity and specificity. Here we present MMCLKin, an attention consistency-guided contrastive learning framework that integrates geometric graph and sequence networks with multi-head attention and multimodal, multiscale contrastive learning to accurately and interpretably predict kinase-inhibitor activity and selectivity. MMCLKin outperforms existing methods across two 3D kinase-drug datasets and demonstrates strong generalizability on ten diverse protein-drug and one mutation-aware datasets, and effectively screens on both known and unknown kinase structures. In-depth analysis of attention coefficients reveals that MMCLKin can identify key residues and molecular functional groups critical for kinase-inhibitor binding. Additionally, ADP-Glo assays confirm that five out of 20 MMCLKin-identified compounds inhibit the pathogenic LRRK2 G2019S mutant, with four exhibiting nanomolar-level potency. Collectively, MMCLKin represents a useful tool for discovering potent and selective kinase inhibitors.

Indexed as

Drug DiscoveryMachine LearningProtein Kinase InhibitorsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanProtein Kinase Inhibitors

Identifiers

PMID41339327
PMCPMC12675671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.